Table 3

Outcomes and adverse events of patients with high-dose daptomycin therapy
Characteristic Total (n = 67) Daptomycin dose (mg/kg)
8 (n = 41) > 8 (n = 26) P value
14-day mortality 11 (16.4%) 6 (14.6%) 5 (19.2%) 0.74
28-day mortality 24 (35.8%) 13 (31.7%) 11 (42.3%) 0.44
In-hospital mortality 33 (49.3%) 20 (48.8%) 13 (50.0%) 0.92
ICU patients (n = 41) 28 (68.3%) 17/24 (70.8%) 11/17 (64.7%) 0.74
Infection-related death 9 (13.4%) 5 (12.2%) 4 (15.4%) 0.73
ICU patients (n = 41) 7 (17.1%) 4/24 (16.7%) 3/17 (17.6%) >0.99
Clinical success 52 (77.6%) 32 (78.0%) 20 (76.9%) 0.91
All bacteremia (n = 54) 43 (79.6%) 27/32 (84.4%) 16/22 (72.7%) 0.32
MRSA (n = 38) 28 (73.7%) 18/23 (78.3%) 10/15 (66.7%) 0.47
Vancomycin MIC ≥ 2 μg/mL (n = 24) 19 (79.2%) 13/14 (92.9%) 6/10 (60%) 0.12
VRE (n = 18) 12 (66.7%) 7/12 (58.3%) 5/6 (83.3%) 0.60
Endocarditis (n = 11) 6 (54.5%) 2/3 (66.7%) 4/8 (50.0%) >0.99
Catheter-related bacteremia (n = 16) 15 (93.8%) 10/11 (90.9%) 5/5 (100%) 0.59
cSSTI (n = 16) 14 (87.5%) 7/9 (77.8%) 7/7 (100%) 0.48
Bone & joint infection (n = 9) 6 (66.7%) 4/6 (66.7%) 2/3 (66.7%) >0.99
Microbiological success 55 (82.1%) 36 (87.8%) 19 (73.1%) 0.19
Adverse events
Cytopenia 47 (70.2%) 28 (68.3%) 19 (73.1%) 0.68
Renal dysfunction 14 (20.9%) 8 (19.5%) 6 (23.1%) 0.73
Elevated AST/ALT 20/66 (30.3%) 12/41 (29.3%) 8/25 (32.0%) 0.82
CPK elevations
Any 16 (29.2%) 7/37 (18.9%) 9/24 (37.5%) 0.11
By definition 4/61 (6.6%) 0/37 (0%) 4/24 (16.7%) 0.02

ALT, alanine aminotransferase; AST, aspartate aminotransferase; CPK, creatine phosphokinase; cSSTI, complicated skin and soft-tissue infection; MIC, minimum inhibitory concentration; MRSA, methicillin-resistant S. aureus; VRE, vancomycin-resistant enterococci.

Lai et al.

Lai et al. BMC Infectious Diseases 2013 13:66   doi:10.1186/1471-2334-13-66

Open Data